“Study of Artificial Intelligence-based Personalized Rituximab Treatment Protocol in Membranous nephropathy”
- Source field
- authorizedApplication.authorizedPartI.trialDetails.clinicalTrialIdentifiers.fullTitle
- Matched term
- artificial intelligence
← Back to the studies fieldPERMANENT CTIS TRIAL DOSSIER
2024-510718-34-00
Study of Artificial Intelligence-based Personalized Rituximab Treatment Protocol in Membranous nephropathy - iRITUX
Public registry stateAuthorised
CLAIM BOUNDARY
This dossier documents a medicinal trial—not proof of efficacy.
Registration, authorisation of a trial application, trial start, result disclosure and marketing authorisation are different facts. The dossier claims neither clinical efficacy nor safety, deployment or causality.
CTIS record ≠ efficacy ≠ marketing authorisationREGISTRY FACTS
What CTIS publishes about this trial
- EUCT number
- 2024-510718-34-00
- Trial status
- Authorised
- Sponsor
- not published
- Trial region
- EEA
- Phase
- 11
- Trial category
- 3
- Low-intervention trial
- yes
- Estimated EU start
- 29 November 2024
- Decision date
- 09 September 2024
- Published
- 21 February 2026
- Estimated end
- 01 October 2031
EXACT AI EVIDENCE
The original text determines inclusion.
Terms count only in allowlisted public CTIS fields. Sponsor, medical condition, phase or a generic software reference alone is not AI evidence.
“Study of Artificial Intelligence-based Personalized Rituximab Treatment Protocol in Membranous nephropathy - iRITUX”
- Source field
- authorizedApplication.authorizedPartI.trialDetails.clinicalTrialIdentifiers.publicTitle
- Matched term
- artificial intelligence
“Model improvement through machine learning”
- Source field
- authorizedApplication.authorizedPartI.trialDetails.trialInformation.trialObjective.secondaryObjectives[14].secondaryObjective
- Matched term
- machine learning
MEDICAL CONTEXT
Conditions and therapeutic areas
Reported medical conditions
- Membranous nephropathymarked as rare disease
Therapeutic areas
- Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutics [E02]25
COUNTRY TRACKS
Every country retains its own published state.
A status in one country is not transferred to another. Decision dates and status histories remain separate source facts.
France
Authorised- First decision
- 09 September 2024
- Latest decision
- 20 February 2026
- Authorised
- Authorised
- Authorised
- Authorised
- Authorised
- Authorised
TRIAL APPLICATIONS
Submission, decision and country state remain separate
IN
AuthorisedINITIAL
- Trial status
- Authorised
- Submitted
- 27 May 2024
- Decided
- 09 September 2024
Decisions09 September 2024 · Authorized
Country statusFrance · Authorised
SM-1
AuthorisedSUBSTANTIAL MODIFICATION
- Trial status
- Authorised
- Submitted
- 24 January 2025
- Decided
- 18 April 2025
Decisions18 April 2025 · Authorized
Country statusFrance · Authorised
SM-2
AuthorisedSUBSTANTIAL MODIFICATION
- Trial status
- Authorised
- Submitted
- 16 January 2026
- Decided
- 20 February 2026
Decisions20 February 2026 · Authorized
Country statusFrance · Authorised
SOURCE-DATED CHRONICLE
Official dates, not an efficacy narrative.
The chronicle sorts published CTIS events. i6eal observation times follow on a separate clock.
Application Submitted Application IN · Authorised
Country Assessment France · Application IN · Authorized
Application Status Application IN · Authorised
Country Decision France · Application IN · Authorized
Application Submitted Application SM-1 · Authorised
Country Assessment France · Application SM-1 · Authorized
Application Status Application SM-1 · Authorised
Country Decision France · Application SM-1 · Authorized
Application Submitted Application SM-2 · Authorised
Country Assessment France · Application SM-2 · Authorized
Application Status Application SM-2 · Authorised
Country Decision France · Application SM-2 · Authorized
Trial Status Observed Authorised
Observed by i6eal
- First observed
- 23 Jul 2026, 13:19
- Last observed
- 23 Jul 2026, 15:03
- Materially modified
- 23 July 2026
Disclosure is a separate registry fact.
No result disclosure is published in this projection. This means neither that results do not exist nor that a deadline has been missed.
PROVENANCE
From the dossier back to the official record
The public CTIS record remains authoritative. The i6eal files are a deterministic, bounded projection.
Open public CTIS record ↗Open CTIS retrieval source ↗Machine-readable dossier · JSON ↓Structured metadata · JSON-LD ↓
i6eal (2026): EU AI Studies Monitor, CTIS trial 2024-510718-34-00, data state 23 July 2026. https://i6eal.de/en/tools/ki-studienmonitor/studie/2024-510718-34-00/